Future cardiology最新文献_第2页

Treatment with vutrisiran in people with transthyretin amyloidosis with cardiomyopathy: a plain language summary. 转甲状腺素淀粉样变合并心肌病患者用乌曲西兰治疗：一个简单的语言总结。

IF 1.6

Future cardiology Pub Date : 2025-05-15 DOI: 10.1080/14796678.2025.2493019

Marianna Fontana, Julian D Gillmore, Ronald M Witteles, Ben Laryea, Marc Dworkin, Ann Payne, Fran Kochman, Satish Eraly, Mathew S Maurer

引用次数: 0

Effect of thymosin α1 on Immune response and organ function in acute aortic dissection surgery: PANDA II trial protocol. 胸腺素α1对急性主动脉夹层手术患者免疫反应和器官功能的影响：PANDA II试验方案。

IF 1.6

Future cardiology Pub Date : 2025-05-14 DOI: 10.1080/14796678.2025.2505401

Hong Liu, Si-Chong Qian, Ying-Yuan Zhang, Cheng-Bin Tang, Hong-Hua Yue, Guo-Liang Fan, Xin Zhao, Yi-Yao Jiang, Fu-Hua Huang, Zhi-Hua Zeng, Wei Wang, Xu-Ran Lu, Xiao-Kang Luo, Xiang-Feng Bai, Xiang-Xiang Zheng, Peng Xie, Chao Ma, Sheng Zhao, Hong-Jia Zhang

{"title":"Effect of thymosin α1 on Immune response and organ function in acute aortic dissection surgery: PANDA II trial protocol.","authors":"Hong Liu, Si-Chong Qian, Ying-Yuan Zhang, Cheng-Bin Tang, Hong-Hua Yue, Guo-Liang Fan, Xin Zhao, Yi-Yao Jiang, Fu-Hua Huang, Zhi-Hua Zeng, Wei Wang, Xu-Ran Lu, Xiao-Kang Luo, Xiang-Feng Bai, Xiang-Xiang Zheng, Peng Xie, Chao Ma, Sheng Zhao, Hong-Jia Zhang","doi":"10.1080/14796678.2025.2505401","DOIUrl":"https://doi.org/10.1080/14796678.2025.2505401","url":null,"abstract":"This multicenter randomized controlled trial evaluates the efficacy of thymosin alpha 1 (Tα1) supplementation in preventing organ dysfunction following acute type A aortic dissection (ATAAD) repair. Over 330 patients will be equally assigned to receive either Tα1 plus standard care or placebo with standard management. The primary endpoint involves calculating the difference in mean postoperative Sequential Organ Failure Assessment (SOFA) scores between groups, measured daily from postoperative days 7. By targeting post-operative immune system imbalance, this study aims to establish a novel therapeutic approach for reducing systemic inflammatory response syndrome (SIRS)-mediated organ injury and improving long-term outcomes in this high-risk population. Results will be disseminated through peer-reviewed publications and international conferences.Trial registration: ClinicalTrials.gov Registry (NCT05339529).","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"1-8"},"PeriodicalIF":1.6,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144077303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

SGLT2 inhibitors across the acute cardiac care spectrum: insights and perspectives. 急性心脏护理谱中的SGLT2抑制剂：见解和观点。

IF 1.6

Future cardiology Pub Date : 2025-05-11 DOI: 10.1080/14796678.2025.2503666

Maurizio Bertaina, Alessandro Galluzzo, Carla Carbonaro, Alessandra Marzulli, Chiara Calcagnile, Pierluigi Sbarra, Luca Franchin, Giacomo Giovanni Boccuzzi, Mario Iannaccone

{"title":"SGLT2 inhibitors across the acute cardiac care spectrum: insights and perspectives.","authors":"Maurizio Bertaina, Alessandro Galluzzo, Carla Carbonaro, Alessandra Marzulli, Chiara Calcagnile, Pierluigi Sbarra, Luca Franchin, Giacomo Giovanni Boccuzzi, Mario Iannaccone","doi":"10.1080/14796678.2025.2503666","DOIUrl":"https://doi.org/10.1080/14796678.2025.2503666","url":null,"abstract":"This review examines the evolving role of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in acute cardiac care. Originally developed as antidiabetic agents, SGLT2i have demonstrated significant and early benefits in chronic heart failure by reducing hospitalizations and cardiovascular mortality across all the ejection fraction spectrum. Recent evidence now suggests that these agents may also offer advantages in acute settings, including acute decompensated heart failure (ADHF) and post - acute myocardial infarction (AMI). Several clinical trials have explored early SGLT2i initiation during hospitalization, reporting improvements in diuretic efficiency, cardiac biomarkers, and favorable remodeling, without notable safety concerns. The present review discusses the multifaceted mechanisms underlying these benefits, which include osmotic diuresis, modulation of neurohormonal activation, anti-inflammatory effects, and direct myocardial protection. Together, these actions not only facilitate decongestion and renal preservation but also enhance cardiac energetics. Current data are promising and support a pivotal role of a SGLT2i as a therapeutic strategy in the whole acute cardiac care setting for their short and long-term benefit. Future research is essential to validate these findings and refine the best patients to be treated with early SGLT2i implementation in the acute cardiac care spectrum.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"1-11"},"PeriodicalIF":1.6,"publicationDate":"2025-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143987592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The challenges in improving myocardial infarction outcomes and the year 2024 in a nutshell. 改善心肌梗死预后的挑战和2024年的概述。

IF 1.6

Future cardiology Pub Date : 2025-05-09 DOI: 10.1080/14796678.2025.2503692

Muhammad Adnan Zaman

引用次数: 0

Nicorandil for prevention of contrast-induced nephropathy in patients undergoing coronary angiography: a meta-analysis. 尼可地尔预防冠脉造影患者造影剂肾病：一项荟萃分析

IF 1.6

Future cardiology Pub Date : 2025-05-09 DOI: 10.1080/14796678.2025.2503640

Ayesha Shaukat, Muhammad Ahmed Zahoor, Laiba Shakeel, Muniba Ijaz, Zobia Ahmad, Wajiha Zehra, Zaigham Ali, Muhammad Umar Mian, Rabbia Munsab, Zainab Awan, Ismat Fatima, Simran Suleman Panjwani, Muhammad Taha, Juvairia Yousuf, Muhammad Hasanain, Muhammad Umair Anjum, Muhammad Omar Larik

{"title":"Nicorandil for prevention of contrast-induced nephropathy in patients undergoing coronary angiography: a meta-analysis.","authors":"Ayesha Shaukat, Muhammad Ahmed Zahoor, Laiba Shakeel, Muniba Ijaz, Zobia Ahmad, Wajiha Zehra, Zaigham Ali, Muhammad Umar Mian, Rabbia Munsab, Zainab Awan, Ismat Fatima, Simran Suleman Panjwani, Muhammad Taha, Juvairia Yousuf, Muhammad Hasanain, Muhammad Umair Anjum, Muhammad Omar Larik","doi":"10.1080/14796678.2025.2503640","DOIUrl":"https://doi.org/10.1080/14796678.2025.2503640","url":null,"abstract":"Introduction: Contrast-induced nephropathy (CIN) is a feared complication of angiographic procedures, resulting in a sudden decline in renal function.Methods: PubMed, ScienceDirect, and Google Scholar were searched for potentially relevant articles from inception till August 2024. The meta-analysis was conducted using RevMan 5.4 with risk ratios (RR), mean differences (MD), and 95% confidence intervals (95% CI) computed.Results: Ultimately, 13 studies were incorporated in the analysis. Nicorandil portrayed a significant protective effect against CIN (RR: 0.42; 95% CI: 0.33-0.54; p < 0.00001). Subgroup analysis revealed the superiority of the oral administration (RR: 0.38; 95% CI: 0.28-0.50; p < 0.00001). Nicorandil was also effective in reducing CIN in renal dysfunction patients (RR: 0.40; 95% CI: 0.27-0.59; p < 0.00001). Blood urea nitrogen (BUN) and cystatin-C 48-hours post-procedure (MD: -0.42; 95% CI: -0.53--0.30; p < 0.00001 and MD: -0.27; 95% CI: -0.51--0.02; p = 0.03, respectively) were superior in the nicorandil cohort. Serum creatinine was significantly lower in patients receiving nicorandil at 24- and 72-hour intervals (MD: -3.18, MD: -4.26, and MD: -3.75, respectively). There were no increased risks of adverse events in the nicorandil cohort.Conclusion: Nicorandil has promising efficacy and safety in reducing the risk of CIN. However, further trials are necessary in order to validate our conclusions.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"1-11"},"PeriodicalIF":1.6,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143986047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating the AltaValve as a novel method for transcatheter mitral valve replacement. 评价AltaValve作为经导管二尖瓣置换术的新方法。

IF 1.6

Future cardiology Pub Date : 2025-05-09 DOI: 10.1080/14796678.2025.2499352

Pablo Vidal-Calés, Pedro L Cepas-Guillén, Juan H Del Portillo, Josep Rodés-Cabau

{"title":"Evaluating the AltaValve as a novel method for transcatheter mitral valve replacement.","authors":"Pablo Vidal-Calés, Pedro L Cepas-Guillén, Juan H Del Portillo, Josep Rodés-Cabau","doi":"10.1080/14796678.2025.2499352","DOIUrl":"https://doi.org/10.1080/14796678.2025.2499352","url":null,"abstract":"Mitral regurgitation (MR) is the most common heart valve disease, and severe MR is associated with a poor prognosis if left untreated. Although surgical repair or replacement constitutes the standard therapy when indicated, many high-risk patients are considered ineligible for surgery. Transcatheter mitral valve replacement (TMVR) offers a less invasive alternative to conventional surgery and may also overcome some of the limitations of percutaneous repair techniques. Currently, multiple TMVR devices are undergoing clinical evaluation, showing promising results. However, challenges mainly related to the complex mitral valve anatomy along with the interaction with the left ventricular outflow tract (LVOT) have resulted in high screen failure rates among TMVR candidates. The AltaValve System features a supra-annular design, ensuring secure fixation in the left atrium above the native mitral valve annulus without anchoring mechanisms that could interfere with the left ventricle (LV). These distinctive attributes aim to address the existing TMVR limitations across a broad patient population and help to avoid complications such as LVOT obstruction, LV damage, and/or prosthesis embolization. Initial safety and feasibility data are encouraging, but a larger cohort of patients with longer follow-up will be essential to confirm the safety and efficacy of the AltaValve system.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"1-12"},"PeriodicalIF":1.6,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144000013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Transcatheter treatment of perimembranous ventricular septal defects: challenges, controversies, and a paradigm shift. 经导管治疗膜周室间隔缺损：挑战、争议和范式转变。

IF 1.6

Future cardiology Pub Date : 2025-05-09 DOI: 10.1080/14796678.2025.2501443

Raymond N Haddad

引用次数: 0

Efficacy and safety of empagliflozin in acute heart failure: a systematic review and meta-analysis. 恩格列净治疗急性心力衰竭的疗效和安全性：一项系统综述和荟萃分析。

IF 1.6

Future cardiology Pub Date : 2025-05-05 DOI: 10.1080/14796678.2025.2499374

Noman Khalid, Muhammad Adil Afzal, Muhammad Abdullah, Ata-Ul Haiy, Yezin Shamoon, Sherif Elkattawy, Muhammad Aamir Laghari, Rahul Vasudev, Shamoon E Fayez, Yasotha Rajeswaran, Gregg M Lanier, Wilbert Aronow

{"title":"Efficacy and safety of empagliflozin in acute heart failure: a systematic review and meta-analysis.","authors":"Noman Khalid, Muhammad Adil Afzal, Muhammad Abdullah, Ata-Ul Haiy, Yezin Shamoon, Sherif Elkattawy, Muhammad Aamir Laghari, Rahul Vasudev, Shamoon E Fayez, Yasotha Rajeswaran, Gregg M Lanier, Wilbert Aronow","doi":"10.1080/14796678.2025.2499374","DOIUrl":"https://doi.org/10.1080/14796678.2025.2499374","url":null,"abstract":"Background: Acute heart failure (AHF) is leading cause of hospitalization and mortality. Empagliflozin, a Sodium Glucose Co-transporter 2 inhibitor (SGLT-2i), has demonstrated benefits in HFrEF and HFpEF, but its role in AHF remains under-explored.Objective: Assess safety and efficacy of empagliflozin in AHF.Methods: A systematic review and meta-analysis adhering to PRISMA 2020 guidelines was conducted. A search on 25 February 2025, identified Phase IIb and III randomized controlled trials (RCTs) involving adults with AHF from databases like Medline®, Cochrane CENTRAL, Embase, and ClinicalTrials.gov. Outcomes included all-cause mortality, HF rehospitalization, cardiovascular deaths, and serious adverse events. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using a random-effects model. Heterogeneity was assessed with I2 and Cochrane Q-statistic.Results: Three RCTs (n = 824) were included. Empagliflozin reduced all-cause mortality (OR: 0.47, 95% CI: 0.29-0.78, p = 0.004) and cardiovascular death (OR: 0.56, 95% CI: 0.38-0.82, p = 0.003) compared to placebo. It also lowered serious adverse events risk (OR: 0.62, 95% CI: 0.44-0.87, p = 0.005) without significantly increasing adverse effects such as acute kidney injury, diabetic ketoacidosis, hypotension, or urinary tract infections. Sensitivity analyses confirmed these findings.Conclusion: Empagliflozin reduces mortality in AHF with a favorable safety profile, highlighting need for further trials.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"1-7"},"PeriodicalIF":1.6,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143978893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A novel familial pathogenic desmoplakin (DSP) gene mutation (c.4751_4752del) presenting as "hot-phase" left-dominant arrhythmogenic cardiomyopathy. 一种新的家族致病性desmoplakin （DSP）基因突变（c.4751_4752del）表现为“热期”左显性心律失常性心肌病。

IF 1.6

Future cardiology Pub Date : 2025-05-05 DOI: 10.1080/14796678.2025.2500835

Victoria Fanucci, Dhaval Chauhan, Nita Ray Chaudhuri, Hemal M Nayak, Utkarsh Kohli

引用次数: 0

Cardiomyopathy genetic testing: insights into demographics, counseling, and cascade screening. 心肌病基因检测：洞察人口统计学，咨询，和级联筛选。

IF 1.6

Future cardiology Pub Date : 2025-05-01 Epub Date: 2025-04-09 DOI: 10.1080/14796678.2025.2484128

Quan M Bui, Elizabeth Silver, Alessia Argiro, Sarah Murray, Lauren Korty, Jorge Silva Enciso, Marcus A Urey, Neil C Chi, Kimberly N Hong, Eric D Adler

{"title":"Cardiomyopathy genetic testing: insights into demographics, counseling, and cascade screening.","authors":"Quan M Bui, Elizabeth Silver, Alessia Argiro, Sarah Murray, Lauren Korty, Jorge Silva Enciso, Marcus A Urey, Neil C Chi, Kimberly N Hong, Eric D Adler","doi":"10.1080/14796678.2025.2484128","DOIUrl":"10.1080/14796678.2025.2484128","url":null,"abstract":"Background: Genetic testing (GT) is clinically indicated for patients with suspected inherited cardiomyopathy (CM) but is underutilized.Methods: This single-center study included patients with CM who underwent outpatient GT from 2018 to 2023. Data were collected from the medical record.Results: A total of 306 patients were included, with a mean age of 62 years and were predominantly male (63%) and White (59%). Heart failure (92%) cardiologists were most likely to order testing, followed by general cardiology (5%) providers at tertiary hospital clinics (89%). The most common phenotypes were hypertrophic (30%), amyloid (29%) and dilated (21%). There were 17% of patients who had a positive test and 53% of patients who had a variant of uncertain significance. Patients with a positive family history had a significantly higher positive yield compared to those without (p < 0.01). Genetic counselors were underutilized (17%). For patients who had a positive test result, only 40% had cascade screening.Conclusions: Outpatient GT for CM was primarily ordered by heart failure cardiologists in tertiary hospital clinics. Cascade screening was low, which may reflect the limited use of genetic counselors. Further research is needed to understand implementation barriers to GT.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"359-364"},"PeriodicalIF":1.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12026082/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0